Literature DB >> 6446256

Chemical pathology of Huntington's disease.

E D Bird.   

Abstract

Huntington's disease (HD), a dominantly inherited disorder of the nervous system, is usually manifest about middle age by dance-like movements. The disorder may occur in children, when epilepsy and rigidity may be the predominant signs. Degeneration of neurons occurs throughout the whole brain, but this is most marked in the basal ganglia. Neurochemical examination of postmortem brain frozen at the time of autopsy has been collected from patients dying with HD and compared with postmortem brain from psychotic patients and cases without neuropsychiatric disease. A number of alterations in neurotransmitters and their biosynthetic enzymes have been found. There are decreased concentrations of the neuroinhibitory transmitter gamma aminobutyric acid and this is associated with increased concentrations of dopamine and serotonin in the basal ganglia. In addition, there is decreased activity of glutamic acid decarboxylase, choline acetyltransferase, angiotensin-converting enzyme, as well as a decreased concentration of the neuropeptide substance P. Various pharmacologic agents have been tried based on the neurochemical alterations, but nothing has been found to be superior to the various neuroleptics in common use.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6446256     DOI: 10.1146/annurev.pa.20.040180.002533

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  18 in total

1.  Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease.

Authors:  P Hantraye; D Riche; M Maziere; O Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.

Authors:  Dan P Covey; Hannah M Dantrassy; Samantha E Yohn; Alberto Castro; P Jeffrey Conn; Yolanda Mateo; Joseph F Cheer
Journal:  Neuropsychopharmacology       Date:  2018-06-01       Impact factor: 7.853

3.  Infection of cultured striatal neurons with a defective HSV-1 vector: implications for gene therapy.

Authors:  A Freese; A Geller
Journal:  Nucleic Acids Res       Date:  1991-12       Impact factor: 16.971

Review 4.  Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease.

Authors:  Laurie Galvan; Véronique M André; Elizabeth A Wang; Carlos Cepeda; Michael S Levine
Journal:  J Huntingtons Dis       Date:  2012

Review 5.  Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

Authors:  L A Raymond; V M André; C Cepeda; C M Gladding; A J Milnerwood; M S Levine
Journal:  Neuroscience       Date:  2011-08-27       Impact factor: 3.590

6.  Immunoreactive beta-endorphin levels in cerebrospinal fluid of children with acute lymphoblastic leukemia: relationship with glucocorticoid therapy and neurological complications.

Authors:  P Iannetti; A Fabbri; G Meloni; M L Moleti; S Ulisse; F Mandelli; A Isidori; C Imperato
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

7.  EMG responses in leg muscles to postural perturbations in Huntington's disease.

Authors:  J Huttunen; V Hömberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-01       Impact factor: 10.154

Review 8.  Huntington disease: genetics and epidemiology.

Authors:  P M Conneally
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

Review 9.  The role of dopamine in Huntington's disease.

Authors:  Carlos Cepeda; Kerry P S Murphy; Martin Parent; Michael S Levine
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

10.  HPLC analysis of somatostatin related peptides in putamen of Huntington's disease patients.

Authors:  G Sperk; G P Reynolds; P Riederer
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.